CXCL10 and neoplasm: This includes the release of CXCL10 and CCL5, inducing the recruitment and activation of CTL229; the release of CXCR3 ligands, such as CXCL10, enhancing the recruitment and cytotoxicity of NK cells,230 and promoting conventional (c)DC1s mediated antigen cross-presentation through IFN-I signaling.231 The type I IFN released upon STING activation can also regulate tumor cells themselves, enabling the expression of MHC-I.231